Aratana Therapeutics (PETX) Misses Q1 EPS by 10c

Aratana Therapeutics (NASDAQ: PETX) reported Q1 EPS of ($0.52), $0.10 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $172 thousand versus the consensus estimate of $140 thousand.

For earnings history and earnings-related data on Aratana Therapeutics (PETX) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• CoStar Group acquires Zonda for $800M, adding new home data
• Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results